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Abstract
Background: The usefulness of procalcitonin (PCT) measurement in critically ill medical patients
with suspected nosocomial infection is unclear. The aim of the study was to assess PCT value for
the early diagnosis of bacterial nosocomial infection in selected critically ill patients.
Methods: An observational cohort study in a 15-bed intensive care unit was performed. Seventy
patients with either proven (n = 47) or clinically suspected but not confirmed (n = 23) nosocomial
infection were included. Procalcitonin measurements were obtained the day when the infection
was suspected (D0) and at least one time within the 3 previous days (D-3 to D0). Patients with
proven infection were compared to those without. The diagnostic value of PCT on D0 was
determined through the construction of the corresponding receiver operating characteristic
(ROC) curve. In addition, the predictive value of PCT variations preceding the clinical suspicion of
infection was assessed.
Results: PCT on D0 was the best predictor of proven infection in this population of ICU patients
with a clinical suspicion of infection (AUROCC = 0.80; 95% CI, 0.68–0.91). Thus, a cut-off value of
0.44 ng/mL provides sensitivity and specificity of 65.2% and 83.0%, respectively. Procalcitonin
variation between D-1 and D0 was calculated in 45 patients and was also found to be predictive of
nosocomial infection (AUROCC = 0.89; 95% CI, 0.79–0.98) with a 100% positive predictive value
if the +0.26 ng/mL threshold value was applied. Comparable results were obtained when PCT
variation between D-2 and D0, or D-3 and D0 were considered. In contrast, CRP elevation,
leukocyte count and fever had a poor predictive value in our population.
Conclusion: PCT monitoring could be helpful in the early diagnosis of nosocomial infection in the
ICU. Both absolute values and variations should be considered and evaluated in further studies.
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Background
In critically ill patients, nosocomial infection is generally
associated with an increased risk of death and a greater
length of stay [1]. The most frequently encountered inten-
sive care unit (ICU)-acquired infections are ventilator
associated pneumonia (VAP) and bacteremia [2,3]. Out-
come can be improved if a prompt and appropriate anti-
biotic therapy is administered [4]. In contrast to patients
with community-acquired sepsis, those who develop
infection in the ICU are under close supervision through
iterative clinical assessment and monitoring of various
blood markers. The onset of infection should therefore be
identified more easily and more quickly in this setting.
However, usual infection-related signs and symptoms can
be missing in such patients because of the deep alterations
of their immune status as well as the exposure to specific
therapies and procedures. As a result, the management of
nosocomial infection is probably delayed in number of
cases. On the other hand, the overuse of antibiotics is a
common feature in ICU [5]. This results from the lack of
specificity of the clinical diagnosis of infection, and the
fear of not treating life-threatening infection in critically
ill patients.
Efforts have been made to develop new biomarkers that
accurately predict sepsis occurrence in such patients.
Among them, serum procalcitonin (PCT) is one of the
most promising [6]. One recently published study showed
that daily monitoring of PCT could allow medical staff to
identify patients with the highest risk of mortality [7]. In
addition, several reports have shown that both PCT eleva-
tion and time course could be helpful in differentiating
between patients who acquired infection in the ICU and
those who did not [8-11]. However, most of these studies
included post-operative patients, and only very few of
them provided the data necessary to assess PCT accuracy
in discriminating suspected from proven sepsis. We there-
fore addressed this issue in an observational cohort study
conducted in our medical ICU.
Methods
The study was conducted from January, 2006 to May,
2007 in a 15-bed medical ICU in a teaching hospital.
Patients
Procalcitonin is routinely assessed in every patient with a
clinically suspected infection [12]. In addition, PCT daily
measurement is used, in addition to clinical judgment, to
assess prognosis, to predict unfavorable outcome and to
customize the length of antibiotic therapy if necessary, as
previously published [7].
Every consecutive patient with a clinical suspicion of VAP
as defined below was prospectively enrolled in an obser-
vational study that aimed to evaluate the effects of imple-
menting local guidelines for the diagnosis and the
management of VAP. Notably, PCT measurement was per-
formed daily from the day of the clinical suspicion in all
of these patients as a part of the study protocol. This study
was approved by the Local Ethic Committee (Comité de
Protection des Personnes, C.H.U. Dijon). No informed
consent was required. Patients in whom the diagnosis of
VAP was considered unlikely as detailed below and
regardless of the PCT level, in the absence of another sus-
pected or proven infection source, formed a control group
of patients with unconfirmed infection.
Over the same period, the clinical and biological charac-
teristics of patients with a clinical suspicion of infection
related to bacteremia, as defined below, were prospec-
tively recorded as part of a regular surveillance study
about blood stream infection.
Only patients with nosocomial bacteremia (see definition
below) were considered for being included in the study.
Among the eligible patients, only those with one PCT
measurement obtained the day the infection was sus-
pected and at least 2 measurements taken within a 3-day
period preceding the event were kept for further analysis.
In addition, patients with candidemia, a recent history
(i.e., within the past 7 days) of proven infection, resusci-
tated cardiac arrest or abdominal surgery were excluded.
Definitions
Ventilator associated pneumonia was considered in every
patient submitted to mechanical ventilation for more
than 2 days if the following conditions were met: (i) new
lung infiltrate on the chest X-ray; (ii) positive tracheal
aspirate cultures (> 106 CFU/mL); (iii) modified Clinical
Pulmonary Infection Score (CPIS) ≥ 6 points (i.e., a CPIS
[13] in which tracheal aspirates culture was considered as
positive if at least 106 CFU/mL bacteria were recovered);
(iv) at least 2 S.I.R.S. criteria.
One episode of bacteremia was defined as the recovery of
any bacterial species, in one or more blood cultures.
Patients in whom Staphylococcus non-aureus were isolated
in blood cultures were not eligible, except if at least 2 con-
secutive samples grew for the same species harboring the
same antibiotic resistance pattern. Blood samples were
obtained by venous puncture before being processed
using the BACTEC system based both on standard aerobic
and anaerobic media coupled with the 9240 automate
(Beckton Dickinson Diagnostic Instrument System, Para-
mus, NJ, USA). Bacteria identification was based on stand-
ard methods. The onset of bacteremia was defined as the
day when the first positive blood culture was obtained.
Bacteremia was considered as nosocomial if the onset
occurred at least 48 hours after ICU-admission.BMC Infectious Diseases 2009, 9:49 http://www.biomedcentral.com/1471-2334/9/49
Page 3 of 9
(page number not for citation purposes)
Measurements of PCT level
The Kryptor® immunoassay was used according to the
manufacturer's instructions (Brahms, Hennigsdorf, Ger-
many). The functional sensitivity of the assay is 0.06 ng/
mL. Patients were excluded from further analysis if the
PCT measurement was not performed within the 12 hours
following the blood sampling because of the risk of a
false-negative result.
Statistical analysis
Values are expressed as mean ± SD unless otherwise
stated. Patients with nosocomial infection were compared
to those without from D-3 to D0. For patients in whom
PCT was obtained on D-1, the ΔPCTD-1, D0 (i.e., PCTD0 -
PCTD-1) was calculated. The same calculation was done for
the patients with PCT measurement available on D-3 and/
or D-2, so that ΔPCTD-2, D0 and ΔPCTD-3, D0 were obtained.
Continuous variables were compared with the Mann
Whitney U test. Categorical variables were compared
using the Chi2-test. In addition, the conformity with the
linear gradient of each continuous variable was checked.
If the linear model was not appropriate to describe its var-
iations, the variable was transformed according to the par-
simonious rule. As a result, the log10PCT was considered
instead of the PCT. The candidate variables were then
manually entered into a logistical regression model if the
associated regression coefficient had a p value less than
0.20 by univariate analysis, and then removed if a p value
less than 0.05 was obtained by multivariate analysis.
The diagnosis accuracy of serum PCT for the diagnosis of
nosocomial infection was expressed as the area under the
corresponding receiver operating characteristic curve
(AUROCC). The optimal threshold value was then
selected. Sensibility, specificity, positive predictive value,
negative predictive value and likelihood ratios were then
calculated. The diagnosis accuracy of each other relevant
marker of infection was compared to those achieved by
PCT through the corresponding AUROCC comparisons.
A p value < 0.05 was considered as statistically significant
for all analyses. STATA software was used for all analyses
(STATA Statistical Package, College Station, Tex., USA).
Results
Patients
Over the study period, VAP was clinically suspected in 89
patients. According to the aforementioned criteria, VAP
was confirmed in 57 patients. Among them, 13 could not
be included because of the presence of at least one of the
exclusion criteria. In addition, PCT was not detected in
another 7. As a result, 37 patients with VAP were included
in the proven nosocomial infection group. During the
same period, 123 episodes of bacteremia were recorded,
among which 72 were considered ICU-acquired. Among
these eligible patients, only 10 could be kept for further
analysis. Actually, 54 met exclusion criteria and the
required PCT measurements were not available in the 8
remaining ones (Figure 1).
Twenty-three of the 32 patients with unconfirmed VAP
were considered for inclusion in the group of patients
with suspected but unproven nosocomial infection. The
remaining ones were excluded in accordance with the
aforementioned criteria.
As shown in Table 1, the baseline characteristics of
patients with proven infection were no different from
those without, except in terms of gender.
Flow chart of the study Figure 1
Flow chart of the study. PCT: procalcitonin; VAP: Ventilator Associated Pneumonia; ICU: Intensive Care Unit.
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Table 1: Baseline characteristics and outcome of the included patients.
Mean (SD) or number (%) Nosocomial infection
n = 47
Unproven nosocomial infection
n = 23
p
Age (year-old) 65.4 (16.2) 58.8 (16.1) 0.113
Female/Male 10 (21.3)/37 (78.7) 11 (47.8)/12 (52.2) 0.046
SAPS II 48.7 (14.6) 50.9 (16.1) 0.570
Underlying condition
Cardiovascular disease 16 (34.0) 7 (30.4) 0.975
Respiratory disease 12 (25.5) 9 (39.1) 0.374
Cirrhosis 5 (10.6) 1 (4.3) 0.668
Diabete mellitus 7 (14.9) 2 (8.7) 0.728
Malignancy 2 (4.2) 4 (17.4) 0.165
Chronic renal failure 4 (8.5) 0 (0.0) 0.372
Admission diagnosis
Sepsis 17 (36.2) 10 (43.5) 0.742
Respiratory distress 20 (42.5) 9 (39.1) 0.988
Shock 17 (36.2) 7 (30.4) 0.836
Neurological disorder 14 (29.8) 7 (30.4) 0.999
Acute renal failure 12 (25.5) 3 (13.1) 0.376
Post-operative 3 (6.4) 1 (4.3) 0.999
ICU length of stay (N. of days) 31.0 (16.2) 30.3 (15.6) 0.861
ICU mortality 42.5% 21.7% 0.150
SAPS: Simplified Acute Physiologic Score; ICU: Intensive Care Unit.
Table 2: Main characteristics of the included patients at the time nosocomial infection was clinically suspected.
Mean (SD) or number (%) Nosocomial infection
n = 47
Unproven nosocomial infection
n = 23
p
Time elapsed from ICU admission (N. of days) 16.1 (10.8) 13.5 (7.9) 0.307
Mechanical ventilation length (N. of days) 18.2 (16.5) 13.5 (9.0) 0.214
Temperature (°C) 37.6 (1.5) 37.6 (1.3) 0.958
Heart rate (bpm) 110 (23) 105 (25) 0.387
Respiratory rate (bpm) 30 (8) 28.1 (7) 0.367
PaO2/FIO2 (mmHg) 226 (125) 217 (119) 0.777
MAP (mmHg) 64 (15) 73 (20) 0.061
Vasopressor requirement (Yes/No) 20 (42) 6 (26.1) 0.282
SOFA score 6.9 (4.1) 7.2 (3.9) 0.706
Previous exposure to steroids 20 (42) 6 (26.1) 0.282
WBC count (103 cells/mm3) 17.1 (11.8) 13.6 (7.0) 0.226
CRP (mg/L) 130.1 (104.3) 95.6 (60.5) 0.238
PCT D0 (ng/mL) 5.5 (9.4) 0.7 (1.2) 0.018
ΔPCTD-1, D0 * +5.8 (1.3) -0.5 (10.4) 0.035
ΔPCTD-2, D0 ** +2.7 (6.9) -0.9 (2.2) 0.048
ΔPCTD-3, D0 *** +4.3 (10.1) -1.2 (2.7) 0.032
Platelet count (cell/mm3) 185,459 (118,375) 235,935 (183,485) 0.028
Creatininemia (μmol/L) 172.6 (136.9) 146.3 (164.9) 0.492
Lactate (mmol/L) 2.1 (0.9) 1.5 (0.4) 0.055
ICU: Intensive Care Unit; MAP: Mean Arterial Pressure; SOFA: Sepsis-related Organ Failure Assessment; WBC: White Blood Cell; CRP: C-reactive 
Protein; PCT: Procalcitonin; ΔPCTD-1, D0 = PCT D0 – PCT D-1; D0: day when infection is clinically suspected.
*available in 45 out of the 70 included patients; **available in 44 out of the 70 included patients; ***available in 51 out of the 70 included patients.BMC Infectious Diseases 2009, 9:49 http://www.biomedcentral.com/1471-2334/9/49
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At the time nosocomial infection was suspected, the
length of ICU stay in the two groups was comparable
(Table 2). However, while no difference was found regard-
ing disease severity as assessed using the SOFA score, there
was a trend towards lower arterial blood pressure, a
greater concentration of blood lactates and a significantly
lower platelet count in the confirmed infection group. It is
worth noting that within the proven infection group,
patients with either VAP or bacteremia were similar,
except a trend toward a greater PaO2/FIO2 ratio in the lat-
ter (Table 3).
Even though patients from both groups were found to be
comparable when considering SIRS criteria, PCT on the
day infection was suspected was significantly higher in
patients with proven infection than in those without (5.5
[9.4] vs. 0.7 [1.2] ng/mL; p = 0.018) (Figure 2). We were
also able to assess PCT variation during the 24 hours pre-
ceding the clinical suspicion of infection in 45 out of the
70 patients. It is worth noting that the absolute difference
between D0 and D-1 was found to be significantly greater
in the population with proven infection than in those
without (+5.8 [1.3] vs. -0.5 [10.1]; p = 0.035). Interest-
ingly, we found that PCT variation between D0 and D-2,
as well as between D0 and D-3, were also markedly differ-
ent between these 2 groups of patients (Table 2).
In an attempt to remove any potential confounding vari-
able, a multivariate analysis model was then constructed
as detailed in the methods section. An important finding
was that PCT on day 0 was the only independent risk fac-
tor associated with proven infection (Odd ratio = 7.69,
95% CI: 2.50–25.0; p < 0.001).
Then, the diagnostic value of PCT was evaluated through
the construction of the corresponding ROC curves. At D0,
the area under the ROC curve was 0.80 (95% CI, 0.68–
0.91). A cut-off value of 0.44 ng/mL provides sensitivity
and specificity of 65.2%, 83.0%, respectively (Table 4).
Although it could be calculated in only 45 patients,
ΔPCTD-1, D0 (i.e., PCT variation between D-1 and D0) was
also found to be accurate in differentiating between
proven and refuted nosocomial infection (Figure 3). Thus,
the corresponding AUROCC was 0.89 (95% CI, 0.79–
0.98), and positive and negative predictive values reached
100% and 68%, respectively, if the +0.26 ng/mL threshold
value was used. The results obtained while considering
ΔPCTD-2, D0 and  ΔPCTD-3, D0 are presented in Table 4.
Finally, when compared with body temperature, leuko-
cyte count and CRP, PCT was the most accurate marker of
infection. It is worth noting that the diagnostic value of
these markers as assessed through the corresponding ROC
curve was poor. The AUROCC were 0.54 (0.40–0.68),
0.59 (0.44–0.75) and 0.58 (0.42–0.75) for temperature,
leukocytes and CRP, respectively (p < 0.01 for all as com-
pared with the AUROCC of PCT on D0).
It is worth noting that similar findings were obtained
when the sole patients with VAP were considered (data
not shown).
Discussion
We show herein that PCT could be helpful for the early
detection of septic complications in critically ill medical
patients. Thus, the level of PCT obtained the day the infec-
tion is suspected is a better predictor than are clinical
parameters such as body temperature and other elements
of the SIRS. Our findings also suggest that low cut-off val-
ues could be used for the diagnosis of ICU-acquired infec-
Table 3: Main characteristics of the included patients with either proven VAP or bacteremia at the time it was clinically suspected.
Mean (SD) or number (%) VAP
n = 37
bacteremia
n = 10
p
Time elapsed from ICU admission (N. of days) 16.8 (11.1) 13.5 (9.8) 0.391
Temperature (°C) 37.4 (1.6) 38.2 (1.3) 0.163
Heart rate (bpm) 110 (23) 112 (23) 0.828
Respiratory rate (bpm) 30 (9) 31 (3) 0.652
PaO2/FIO2 (mmHg) 208 (110) 292 (157) 0.074
MAP (mmHg) 63 (15) 69 (14) 0.241
Vasopressor requirement (Yes/No) 20 (42) 6 (26.1) 0.282
SOFA score 7.0 (4.6) 5.9 (4.7) 0.489
Previous exposure to steroids 20 (42) 6 (26.1) 0.282
WBC count (103 cells/mm3) 17.9 (12.8) 14.3 (7.3) 0.394
CRP (mg/L) 137.6 (111.1) 98.6 (66.8) 0.382
PCT D0 (ng/mL) 4.7 (8.4) 8.5 (12.3) 0.261
ΔPCTD-1, D0 * +4.7 (9.5) +10.9 (13.5) 0.189
Platelet count (cell/mm3) 256,912 (207,429) 262,800 (231,402) 0.939
Creatininemia (μmol/L) 166.8 (131.6) 192.8 (160.2) 0.602
Lactate (mmol/L) 2.0 (0.9) 2.6 (1.1) 0.258BMC Infectious Diseases 2009, 9:49 http://www.biomedcentral.com/1471-2334/9/49
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tion in this particular setting. This illustrates the difficulty
of determining PCT cut-off values for the diagnosis of
ICU-acquired infection in critically ill patients.
The kinetic analysis of PCT might help to circumvent this
drawback and should be preferred in this setting. Indeed,
we showed here that a PCT elevation of at least 0.26 ng/
mL over the previous 24 hours was strongly associated
with the diagnosis of infection since the positive predic-
tive value reached 100%. It is, however, worth noting that
the negative predictive value of PCT using such threshold
values was quite low. This reflects the low sensitivity of
PCT in our study population and thus underlines the risk
of false negative results.
Our results agree in part with those reported by Luyt et al
[14]. These authors found that the positive predictive
value of an increase in PCT within the previous 5 days
reached 79% in 73 patients with clinically suspected VAP.
In contrast, the diagnosis accuracy of PCT elevation on the
day VAP was clinically suspected was poor. Thus, positive
and negative predictive values were 43% and 53%, respec-
tively, if a threshold of 0.5 ng/mL was applied. The study
population was, however, markedly different from ours
since it comprised patients with sepsis on admission. In
addition, half of them had undergone surgery prior to
VAP. We believe that these factors could have led to an
underestimation of the diagnostic value of PCT, and could
account for the discrepancies between these findings and
ours [15,16]. Other authors have reported that the combi-
nation of PCT and CPIS could provide very high predic-
Kinetic of procalcitonin in the serum of patients with (black line) or without (gray line) nosocomial infection in the ICU Figure 2
Kinetic of procalcitonin in the serum of patients with (black line) or without (gray line) nosocomial infection in 
the ICU. PCT: procalcitonin.*: p < 0.05.
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tive values regarding the diagnosis of VAP, but in these
studies more than half of the eligible patients were
excluded because of previous sepsis [17].
It is well established that such conditions (i.e., prior sur-
gery, sepsis, renal dysfunction, etc...) could diminish the
diagnostic value of PCT. Thus, greater values should be
expected in post-operative patients as well as in patients
with acute renal failure [10,11,15]. We have also shown
that the diagnosis accuracy of PCT in critically ill patients
with bacteremia was lower if there had been a previous
episode of sepsis and could be different according to the
isolated pathogen [18,19]. The assessment of PCT kinetics
could therefore be proposed to overcome this drawback.
Although it could not be determined in all our patients,
PCT elevation within the 24 hours preceding the clinical
suspicion of infection seems to be strongly associated
with the risk of proven infection.
Several limitations should however be mentioned. First,
our findings were obtained from a single center in a
selected population and cannot necessarily be extended to
other critically ill patients. Accordingly, the study design
led to the exclusion of numbers of early-onset ICU-
acquired infection episodes. As suggested by the long time
generally elapsed between admission and clinical suspi-
cion of infection, our findings might be applicable to the
only patients with late-onset nosocomial infection. Sec-
ond, PCT on D-1 could not be obtained in all of the
included patients, which could have altered our findings.
Third, most of the proven infections were VAP. One could
therefore argue that we did not use a reliable diagnostic
tool since no invasive procedure had been conducted.
Thus, recently published studies have emphasized the lack
of diagnostic value of the CPIS [20,21]. As a result, epi-
sodes of VAP might have been missed in the group of
unconfirmed infection while an incorrect diagnosis of
proven infection may have been made in the remaining
patients. We should admit therefore that our findings
regarding PCT value might have been different if VAP
diagnosis had relied on other criteria. In addition, we did
not consider nosocomial infections caused by virus, given
the expected lack of reliability of PCT as a diagnostic tool
in this context. Finally, since PCT elevation is thought to
be greater in the patients with bacteremia than in those
with VAP, one cannot exclude that PCT levels had been
overestimated in the proven infection group. However,
similar findings were obtained when the only patients
with either suspected or proven VAP were considered.
Finally, it is worth noting that PCT daily measurement
cost could compromise the translation of our findings
into the clinical practice. However, our findings suggest
that PCT measurement twice a week instead of once a day
could also provide relevant information regarding kinetic
at lower cost.
Conclusion
Our results suggest that even when mild, any increase in
PCT in a critically ill patient should contribute to warn the
physician of the risk of infection, in addition to clinical
findings, after excluding other obvious causes of PCT ele-
vation such as recent surgery or cardiac arrest. Additional
larger studies are needed to confirm these findings and to
establish the basis of an interventional study that would
aim to compare the management of critically ill patients
with or without the information brought by daily moni-
toring of PCT levels.
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ROC curves of PCT D0 (A) and ΔPCTD-1, D0 *(B) for differentiating between patients with or without nosocomial infection in  the ICU: AUROCC = 0.80; 95% CI, 0.68–0.91 and 0.89; 95% CI, 0.79–0.98, respectively Figure 3
ROC curves of PCT D0 (A) and ΔPCTD-1, D0 *(B) for differentiating between patients with or without nosoco-
mial infection in the ICU: AUROCC = 0.80; 95% CI, 0.68–0.91 and 0.89; 95% CI, 0.79–0.98, respectively. ICU: 
intensive care unit; PCT: procalcitonin; ΔPCTD-1, D0 = PCT D0 – PCT D-1; D0: day when infection is suspected. *available in 45 
out of the 70 included patients.
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